Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026)
Amarin Corp Plcuk (AMRN) reported Return on Capital Employed of 0.75% for Q1 2026, up 367.0% year-over-year from 0.16% in Q1 2025, and up 60.81% quarter-over-quarter from 1.91% in Q4 2025.
Amarin Corp Plcuk (AMRN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Return on Capital Employed data on file, last reported at 0.75% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 0.75%, up 367.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.75% (up 367.0% YoY), and the FY2025 annual result was 1.86%, up 147.0% from the prior year.
- Return on Capital Employed improved to 0.75% in Q1 2026 per AMRN's latest filing, from 1.91% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 2.44% in Q2 2024 and troughed at 16.6% in Q4 2022.
- A 5-year average of 6.44% and a median of 4.42% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed slumped 1701 bps in 2022, then soared 1427 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 16.6% in 2022, then jumped by 86 bps to 2.33% in 2023, then slumped by 54 bps to 3.59% in 2024, then soared by 47 bps to 1.91% in 2025, then surged by 61 bps to 0.75% in 2026.
- Business Quant data shows AMRN's Return on Capital Employed at 0.75% in Q1 2026, 1.91% in Q4 2025, and 4.94% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -6.84% |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -0.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75% |
| Dec 31, 2025 | -1.91% |
| Sep 30, 2025 | -4.94% |
| Jun 30, 2025 | -7.95% |
| Mar 31, 2025 | -4.42% |
| Dec 31, 2024 | -3.59% |
| Sep 30, 2024 | 1.75% |
| Jun 30, 2024 | 2.44% |
| Mar 31, 2024 | -1.65% |
| Dec 31, 2023 | -2.33% |
| Sep 30, 2023 | -12.41% |
| Jun 30, 2023 | -9.51% |
| Mar 31, 2023 | -15.09% |
| Dec 31, 2022 | -16.60% |
| Sep 30, 2022 | -13.44% |
| Jun 30, 2022 | -15.65% |
| Mar 31, 2022 | -3.35% |
| Dec 31, 2021 | 0.41% |
| Sep 30, 2021 | 0.23% |
| Jun 30, 2021 | 1.18% |